Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
JIM CRAMER
The Power of Personalization: Cramer's 'Mad Money' Recap
By Scott Rutt
Oct 24, 2018 11:04 PM EDT
PRESS RELEASES
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By Business Wire
Jan 7, 2021 4:05 PM EST
PRESS RELEASES
Verastem Oncology Appoints Frank Neumann, M.D., Ph.D., As Chief Medical Officer
By Business Wire
Jan 6, 2021 9:13 AM EST
PRESS RELEASES
Verastem Oncology To Present At The H.C. Wainwright BioConnect 2021 Conference
By Business Wire
Jan 5, 2021 7:00 AM EST
PRESS RELEASES
Verastem Oncology Announces New Data Published In The Lancet Oncology Supports Potential Of VS-6766 As Treatment For RAS Mutant Tumors
By Business Wire
Oct 28, 2020 8:01 PM EDT
PRESS RELEASES
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By Business Wire
Oct 6, 2020 7:00 AM EDT
PRESS RELEASES
Verastem Oncology Announces Closing Of COPIKTRA® (duvelisib) Sale To Secura Bio
By Business Wire
Sep 30, 2020 8:54 AM EDT
PRESS RELEASES
Verastem Oncology Announces Presentation Of Updated Phase 1/2 FRAME Study Data At The 2nd Annual RAS-Targeted Drug Development Summit
By Business Wire
Sep 16, 2020 7:00 AM EDT
PRESS RELEASES
Verastem Oncology To Present At Upcoming Investor Conferences
By Business Wire
Sep 10, 2020 4:05 PM EDT
PRESS RELEASES
Verastem Oncology Signs Definitive Agreement To Sell COPIKTRA® (duvelisib) Rights To Secura Bio To Focus On Development Of VS-6766 And Defactinib In KRAS Mutant Solid Tumors
By Business Wire
Aug 10, 2020 8:30 AM EDT
PRESS RELEASES
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By Business Wire
Jul 6, 2020 7:00 AM EDT
PRESS RELEASES
Verastem Oncology Announces Presentation Of Preclinical Data Supporting The Combination Of VS-6766 And Defactinib In Metastatic Uveal Melanoma
By Business Wire
Jun 22, 2020 4:05 PM EDT
PRESS RELEASES
Verastem Oncology To Present At The Jefferies Virtual Healthcare Conference
By Business Wire
May 28, 2020 7:00 AM EDT
PRESS RELEASES
Verastem Oncology Appoints John H. Johnson To Its Board Of Directors
By Business Wire
Apr 23, 2020 8:38 AM EDT
PRESS RELEASES
Verastem Oncology Announces 2020 Annual Meeting Of Stockholders To Be Held As Virtual Meeting
By Business Wire
Apr 21, 2020 5:18 PM EDT
PRESS RELEASES
Verastem Oncology Announces Investor Conference Call To Discuss Clinical Data From Investigator-initiated RAF/MEK And FAK Combination Study In KRAS Mutant Solid Tumors
By Business Wire
Apr 20, 2020 7:00 AM EDT
PRESS RELEASES
Verastem Oncology Announces Presentation Of Clinical Data From Investigator-initiated RAF/MEK And FAK Combination Study In KRAS Mutant Solid Tumors At The American Association For Cancer Research 2020 Virtual Annual Meeting I
By Business Wire
Apr 13, 2020 6:05 PM EDT
PRESS RELEASES
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By Business Wire
Apr 7, 2020 4:05 PM EDT
PRESS RELEASES
Verastem Oncology Announces New Strategic Direction To Advance Its Clinical Development Programs
By Business Wire
Feb 28, 2020 6:05 AM EST
PRESS RELEASES
Verastem Oncology Announces $100 Million Private Placement Offering Of Common Stock To Premier Life Sciences Investors
By Business Wire
Feb 28, 2020 6:00 AM EST
PRESS RELEASES
Verastem Oncology Announces Dosing Of First Patient In CSPC's Chinese Study Evaluating COPIKTRA® (Duvelisib) In Patients With Relapsed Or Refractory Follicular Lymphoma
By Business Wire
Jan 29, 2020 7:06 AM EST
PRESS RELEASES
Verastem Oncology Announces Global Licensing Agreement With Chugai Pharmaceutical Co., Ltd. To Develop And Commercialize RAF/MEK Inhibitor CH5126766
By Business Wire
Jan 8, 2020 7:00 AM EST
JIM CRAMER
The Power of Personalization: Cramer's 'Mad Money' Recap
By Scott Rutt
Oct 24, 2018 11:04 PM EDT
JIM CRAMER
Ferrari, Paychex, First American: 'Mad Money' Lightning Round
By Scott Rutt
Oct 24, 2018 11:04 PM EDT
HEALTH
Verastem Shares Jump On Cancer Drug Data - Biotech Movers
By Armie Margaret Lee
Sep 6, 2017 11:11 AM EDT